查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080392

臨床試驗市場：2026-2032年全球市場預測（依服務、研究設計、臨床階段、服務模式、治療領域及申辦方分類）

Clinical Trials Market by Offering, Trial Design, Clinical Phase, Delivery Model, Therapeutic Area, Sponsorship - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，臨床試驗市場將成長至 1,735.5 億美元，複合年成長率為 9.59%。

主要市場統計數據
基準年 2025 913.7億美元
預計年份：2026年 999.2億美元
預測年份 2032 1735.5億美元
複合年成長率 (%) 9.59%

臨床試驗執行摘要

臨床試驗仍然是支持藥物、生技藥品、疫苗、醫療設備和診斷技術創新研發的證據來源，它將科學假設轉化為監管機構認可的安全性、有效性和相對價值證明。隨著申辦方致力於精準醫療、罕見疾病計畫、細胞和基因療法以及分散式臨床試驗模式，該領域不斷發展演變；同時，監管機構也要求加強對多樣性、資料完整性和病患安全的管控。

臨床試驗開展方式的變革性變化。

臨床試驗正從傳統的、以研究中心為中心、以紙本文件為基礎的模式，轉向混合式和分散式模式，這些模式結合了遠端醫療、電子知情同意書（eConsent）、電子評估證書（eCOA）、遠端患者監護、直接送達患者以及居家醫療服務。雖然這種轉變提高了病患的就診率和留存率，但也對網路安全、隱私管治、醫療設備驗證、終點可靠性和方案設計提出了更高的要求。

人工智慧在臨床試驗中的累積影響

人工智慧 (AI) 對臨床試驗計劃、受試者識別、研究中心選擇、方案最佳化、資料審核、醫學編碼、藥物警戒、累積訊號檢測和文件智慧等方面都產生了累積性的影響。將 AI 應用於檢驗的資料集和管治的工作流程，可以減輕人工審核的負擔，及早發現操作風險，識別受試者招募障礙，並支持更準確的可行性建模。

全球臨床試驗的關鍵區域性見解

北美憑藉其成熟的研究基礎設施、生物製藥領域強大的研發投入、一流的大學附屬醫療中心、經驗豐富的首席臨床實驗網路以及完善的臨床研究機構（CRO）生態系統，仍然是高價值的臨床試驗中心。美國在註冊臨床試驗數量和監管影響力方面主導，而加拿大則在癌症、罕見疾病、疫苗和公共衛生領域擁有強大的研究能力，並得到完善的倫理和監管流程的支持。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協地區，新加坡、泰國、馬來西亞、越南、印尼和菲律賓等國正透過醫療現代化、建立區域製造網路、投資數位醫療以及更多參與跨國研究，來加強臨床試驗生態系統。新加坡因其高效的監管和生物醫學研究能力而廣受認可，而更大的東協市場則支持受試者招募的多樣性以及在真實臨床環境中接觸患者的便利性。

對主要臨床試驗市場關鍵國家的洞察

美國仍然是最具影響力的臨床研究市場，這得益於美國食品藥物管理局(FDA) 的監管、雄厚的生物醫學研究資金、廣泛的臨床實驗中心網路、一流的大學醫院以及涵蓋眾多治療領域的專業知識。加拿大以其高品質的研究中心、可預測的監管、在癌症和疫苗領域的實力以及健全的公共衛生基礎設施而備受推崇。同時，墨西哥和巴西則擁有多元化的人口、大規模的都市區醫療保健系統以及在拉丁美洲不斷擴展的私人臨床研究能力。

為臨床試驗領導者提供的實用建議

行業領導者應優先考慮以患者為中心的方案設計、早期可行性分析、具有代表性的招募策略和多樣性行動計劃，以提高受試者入組率、保留率和證據的普遍適用性。申辦者和臨床研究機構應拓展其混合試驗能力，並規範供應商合格、醫療設備驗證、遠端監查程序、電子源資料管理和資料互通性。

臨床試驗分析的調查方法

本調查方法整合了來自監管機構、臨床試驗註冊中心、公共衛生機構、申辦者資訊披露、同行評審文獻和行業出版刊物的二手研究資料。主要資訊來源包括ClinicalTrials.gov、世界衛生組織國際臨床試驗註冊平台（WHO ICTRP）、美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）、歐盟委員會臨床試驗資訊系統（CTIS）資訊、國家監管機構、公共臨床試驗註冊中心和權威科學期刊。

結論：臨床試驗的未來

臨床試驗正朝著更數位化、分散化和智慧主導的階段發展，在這個階段，卓越的營運和嚴謹的科學性必須齊頭並進。這種趨勢是由分散式執行、人工智慧驅動的分析、監管協調、真實世界數據（REW）的整合以及對患者參與度的日益成長的期望共同塑造的。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 臨床試驗市場：依產品/服務分類

  • 服務
    • 分析測試服務
    • 生物分析檢測服務
    • 臨床試驗資料管理服務
    • 臨床試驗管理和監測
    • 醫用照明
    • 受試者的招募與維護
    • 監管和安全監測
    • 安全和藥物安全監測
  • 軟體
    • 臨床試驗管理平台
    • eConsent
    • 電子數據採集（EDC）
    • 電子病患報告結果（ePRO）系統
    • 隨機化與研究材料管理（RTSM）系統
    • 遠端資料檢驗

第8章 臨床試驗市場：依研究設計分類

  • 擴大存取權限
  • 干預試驗
    • 適應性臨床試驗
    • 非隨機對照試驗
    • 隨機對照試驗
  • 觀察性研究
    • 分析研究
      • 病例對照研究
      • 隊列研究
      • 前瞻性研究
      • 回顧性研究
      • 橫斷面研究
    • 說明研究
      • 病例報告
      • 病例係列
      • 目標群體

第9章 臨床試驗市場：依臨床階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段
  • 臨床前階段

第10章 臨床試驗市場：依服務模式分類

  • 全方位服務外包（FSO）
  • 功能服務供應商(FSP)
  • 混合外包

第11章 臨床試驗市場：依治療領域分類

  • 循環系統
  • 內分泌學
  • 胃腸病學
  • 免疫學
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 罕見疾病
  • 呼吸系統疾病

第12章 臨床試驗市場：依申辦方分類

  • 學術機構
  • 公司
  • 政府
  • 個人

第13章 臨床試驗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 臨床試驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 臨床試驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Accenture plc
  • Aragen Life Sciences Limited
  • Castor EDC BV
  • Celerion, Inc.
  • Charles River Laboratories International, Inc.
  • Cliantha Research Limited
  • CMIC Holdings Co., Ltd.
  • Eurofins Scientific SE
  • Fortrea Holdings Inc.
  • ICON plc
  • IQVIA Holdings Inc.
  • JSS Medical Research, Inc.
  • Laboratory Corporation of America Holdings
  • Lambda Therapeutic Research Limited
  • LGC Limited
  • Lindus Health Limited
  • Medable, Inc.
  • Medidata Solutions, Inc.
  • Medpace Holdings, Inc.
  • Novotech Health Holdings Pty Ltd
  • OpenClinica, LLC
  • Parexel International Corporation
  • Pharmaron, Inc.
  • Science 37 Holdings, Inc.
  • Syneos Health, Inc.
  • Syngene International Ltd
  • Thermo Fisher Scientific Inc.
  • THREAD Research, Inc.
  • Veeva Systems Inc.
  • Worldwide Clinical Trials, Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-434CCDA05152

The Clinical Trials Market is projected to grow by USD 173.55 billion at a CAGR of 9.59% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 91.37 billion
Estimated Year [2026] USD 99.92 billion
Forecast Year [2032] USD 173.55 billion
CAGR (%) 9.59%

Clinical Trials Executive Summary

Clinical trials remain the evidence engine behind drug, biologic, vaccine, medical device, and diagnostic innovation, translating scientific hypotheses into regulated proof of safety, efficacy, and comparative value. The sector is advancing as sponsors pursue precision medicine, rare disease programs, cell and gene therapies, and decentralized clinical trial models while regulators demand stronger diversity, data integrity, and patient-safety controls.

Registered clinical trial activity is broad and global: ClinicalTrials.gov has listed more than 500,000 studies, while the World Health Organization's ICTRP aggregates records from multiple national and regional registries. This scale underscores a market defined by complex site networks, contract research organization partnerships, electronic data capture, risk-based monitoring, real-world evidence, pharmacovigilance, and increasingly AI-enabled clinical trial operations.

Transformative Shifts in the Clinical Trials Landscape

The clinical trials landscape is shifting from site-centric, paper-heavy execution toward hybrid and decentralized clinical trials that combine in-person visits with telehealth, eConsent, eCOA, remote patient monitoring, direct-to-patient logistics, and home health services. This transition is improving patient access and retention while requiring stronger cybersecurity, privacy governance, device validation, endpoint reliability, and protocol design discipline.

Regulatory modernization is also reshaping operations. The European Union Clinical Trials Regulation and Clinical Trials Information System have centralized EU submissions, while the U.S. Food and Drug Administration has advanced guidance on decentralized trial conduct, diversity action plans, electronic systems, and real-world data. Sponsors are responding by building quality-by-design frameworks, adaptive trial capabilities, risk-based quality management, and more resilient global supply chains for investigational products.

Cumulative Impact of Artificial Intelligence on Clinical Trials

Artificial intelligence is becoming a cumulative force across clinical trial planning, patient identification, site selection, protocol optimization, data review, medical coding, pharmacovigilance, safety signal detection, and document intelligence. When applied to validated datasets and governed workflows, AI can reduce manual review burden, surface operational risk earlier, identify recruitment barriers, and support more precise feasibility modeling.

The impact is not purely technological; it is regulatory and ethical. AI use in clinical trials must be explainable, auditable, privacy-preserving, and aligned with Good Clinical Practice. Leading organizations are adopting human-in-the-loop oversight, model monitoring, bias assessment, validation documentation, and controlled deployment to ensure that algorithmic decisions strengthen evidence quality rather than introduce hidden risk.

Key Regional Insights Across Global Clinical Trials

North America remains a high-value clinical trials hub due to mature research infrastructure, strong biopharmaceutical R&D investment, major academic medical centers, experienced investigator networks, and a sophisticated clinical research organization ecosystem. The United States leads in registered trial activity and regulatory influence, while Canada contributes strong oncology, rare disease, vaccine, and public health research capacity supported by established ethics and regulatory processes.

Europe benefits from harmonization under the European Union Clinical Trials Regulation and CTIS, although sponsors continue to manage country-level ethics, language, contracting, data protection, and reimbursement differences. The region remains prominent in oncology, immunology, cardiovascular, metabolic, and advanced therapy trials, supported by public research networks and high standards for patient protection.

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, Australia, and ASEAN markets combine large patient pools, improving regulatory timelines, digital health adoption, and strong investigator networks. Latin America offers recruitment advantages through Brazil and Mexico, where diverse populations and expanding private healthcare capacity support multisite studies. The Middle East is emerging through investment in precision medicine, genomics, specialty hospitals, and digital health infrastructure, while Africa is strengthening trial readiness through infectious disease research experience, vaccine studies, public health partnerships, and expanding ethics review capacity.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, countries such as Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines are strengthening clinical trial ecosystems through healthcare modernization, regional manufacturing links, digital health investment, and growing participation in multinational studies. Singapore is widely recognized for regulatory efficiency and biomedical research capacity, while larger ASEAN markets support recruitment diversity and real-world patient access.

The GCC is investing in precision medicine, genomics, digital health, and hospital infrastructure, creating opportunities for specialty trials in oncology, metabolic disease, rare disorders, and population-health research. The European Union provides a large harmonized regulatory environment through CTIS and the Clinical Trials Regulation, although operational execution still requires local expertise in ethics submissions, site contracting, language requirements, and national health systems.

BRICS countries are increasingly important for recruitment scale, therapeutic diversity, scientific capacity, and cost-efficient clinical operations, with China, India, and Brazil playing visible roles in global study portfolios. G7 markets continue to set global standards for advanced therapies, regulatory science, data integrity, patient safety, and sponsor funding. NATO countries, particularly those in North America and Europe, offer strong data protection frameworks, resilient medical supply chains, mature research institutions, and established compliance cultures that support complex global trials.

Key Country Insights Across Leading Clinical Trial Markets

The United States remains the most influential clinical research market, supported by U.S. Food and Drug Administration oversight, deep biomedical funding, extensive site networks, leading academic medical centers, and broad therapeutic expertise. Canada is valued for high-quality research centers, predictable regulation, oncology and vaccine capabilities, and strong public health infrastructure, while Mexico and Brazil provide access to diverse populations, large urban healthcare systems, and growing private clinical research capacity across Latin America.

The United Kingdom has reinforced its research competitiveness through Medicines and Healthcare products Regulatory Agency reforms, National Health Service-linked data assets, genomics initiatives, and established trial networks. Germany, France, Italy, and Spain maintain strong sponsor presence, investigator expertise, hospital infrastructure, and participation in European multicountry studies, while Russia retains scientific and clinical capacity but faces geopolitical, sanctions-related, logistics, and operational constraints that can affect trial continuity and sponsor participation.

China has become a major clinical trial destination as regulatory reforms, faster review pathways, domestic biopharmaceutical growth, and large hospital networks accelerate innovation. India offers population scale, digital health infrastructure, cost-efficient operations, and strengthened ethics oversight, making it important for global and local studies. Japan provides advanced clinical standards, strong regulatory science, and aging-population research relevance, while Australia is recognized for early-phase trial incentives, high-quality sites, and efficient start-up pathways. South Korea continues to stand out for digital infrastructure, oncology research, electronic medical record maturity, and globally competitive hospital networks.

Actionable Recommendations for Clinical Trial Leaders

Industry leaders should prioritize patient-centric protocol design, early feasibility analytics, representative recruitment strategies, and diversity action planning to improve enrollment, retention, and evidence generalizability. Sponsors and clinical research organizations should expand hybrid trial capabilities while standardizing vendor qualification, device validation, remote monitoring procedures, electronic source data controls, and data interoperability.

Vendors should also build AI governance into clinical operating models rather than treating AI as a standalone tool. This includes controlled pilots, validated use cases, audit trails, model-risk management, bias testing, privacy safeguards, and staff training. Organizations that align digital innovation with Good Clinical Practice compliance, privacy requirements, investigator usability, and patient safety will be better positioned to improve cycle efficiency and protect data quality.

Research Methodology for Clinical Trials Analysis

The research methodology integrates secondary research from regulatory agencies, clinical trial registries, public health organizations, sponsor disclosures, peer-reviewed literature, and industry publications. Core sources include ClinicalTrials.gov, WHO ICTRP, U.S. Food and Drug Administration, European Medicines Agency, European Commission CTIS information, national regulators, public clinical trial registries, and recognized scientific journals.

Findings are validated through triangulation across trial activity, regulatory developments, technology adoption, regional policy shifts, inspection priorities, therapeutic-area trends, and sponsor investment patterns. The analysis emphasizes verified market signals, cross-regional comparability, and evidence-based interpretation to support strategic decision-making for sponsors, clinical research organizations, sites, investors, and technology providers without relying on market sizing or forecasting.

Conclusion: The Future of Clinical Trials

Clinical trials are entering a more digital, distributed, and intelligence-driven phase in which operational excellence and scientific rigor must advance together. The landscape is being shaped by decentralized execution, AI-enabled analytics, regulatory harmonization, real-world evidence integration, and stronger expectations for inclusive patient participation.

Organizations that combine patient access, high-quality data capture, compliant technology, and global execution discipline will be best positioned to compete. The future of clinical trials will favor sponsors and partners that can deliver faster, safer, and more representative evidence without compromising transparency, ethics, data integrity, or regulatory confidence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Clinical Trials Market, by Offering

  • 7.1. Services
    • 7.1.1. Analytical Testing Services
    • 7.1.2. Bioanalytical Testing Services
    • 7.1.3. Clinical Trial Data Management Services
    • 7.1.4. Clinical Trial Management & Monitoring
    • 7.1.5. Medical Writing
    • 7.1.6. Patient Recruitment & Retention
    • 7.1.7. Regulatory & Safety Monitoring
    • 7.1.8. Safety & Pharmacovigilance
  • 7.2. Software
    • 7.2.1. Clinical Trial Management Platform
    • 7.2.2. eConsent
    • 7.2.3. Electronic Data Capture
    • 7.2.4. Electronic Patient-Reported Outcomes (ePRO) Systems
    • 7.2.5. Randomization & Trial Supply Management (RTSM) Systems
    • 7.2.6. Remote Source Data Verification

8. Clinical Trials Market, by Trial Design

  • 8.1. Expanded Access
  • 8.2. Interventional
    • 8.2.1. Adaptive Clinical Trials
    • 8.2.2. Non-Randomized Controlled Trials
    • 8.2.3. Randomized Controlled Trials
  • 8.3. Observational
    • 8.3.1. Analytical Study
      • 8.3.1.1. Case-Control Studies
      • 8.3.1.2. Cohort Studies
      • 8.3.1.2.1. Prospective
      • 8.3.1.2.2. Retrospective
      • 8.3.1.3. Cross-Sectional Studies
    • 8.3.2. Descriptive Study
      • 8.3.2.1. Case Reports
      • 8.3.2.2. Case Series
      • 8.3.2.3. Population

9. Clinical Trials Market, by Clinical Phase

  • 9.1. Phase I
  • 9.2. Phase II
  • 9.3. Phase III
  • 9.4. Phase IV
  • 9.5. Preclinical

10. Clinical Trials Market, by Delivery Model

  • 10.1. Full Service Outsourcing (FSO)
  • 10.2. Functional Service Provider (FSP)
  • 10.3. Hybrid Outsourcing

11. Clinical Trials Market, by Therapeutic Area

  • 11.1. Cardiology
  • 11.2. Endocrinology
  • 11.3. Gastroenterology
  • 11.4. Immunology
  • 11.5. Infectious Disease
  • 11.6. Neurology
  • 11.7. Oncology
  • 11.8. Rare Disease
  • 11.9. Respiratory Disorders

12. Clinical Trials Market, by Sponsorship

  • 12.1. Academic
  • 12.2. Company
  • 12.3. Government
  • 12.4. Individual

13. Clinical Trials Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Clinical Trials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Clinical Trials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Accenture plc
  • 17.2. Aragen Life Sciences Limited
  • 17.3. Castor EDC B.V.
  • 17.4. Celerion, Inc.
  • 17.5. Charles River Laboratories International, Inc.
  • 17.6. Cliantha Research Limited
  • 17.7. CMIC Holdings Co., Ltd.
  • 17.8. Eurofins Scientific SE
  • 17.9. Fortrea Holdings Inc.
  • 17.10. ICON plc
  • 17.11. IQVIA Holdings Inc.
  • 17.12. JSS Medical Research, Inc.
  • 17.13. Laboratory Corporation of America Holdings
  • 17.14. Lambda Therapeutic Research Limited
  • 17.15. LGC Limited
  • 17.16. Lindus Health Limited
  • 17.17. Medable, Inc.
  • 17.18. Medidata Solutions, Inc.
  • 17.19. Medpace Holdings, Inc.
  • 17.20. Novotech Health Holdings Pty Ltd
  • 17.21. OpenClinica, LLC
  • 17.22. Parexel International Corporation
  • 17.23. Pharmaron, Inc.
  • 17.24. Science 37 Holdings, Inc.
  • 17.25. Syneos Health, Inc.
  • 17.26. Syngene International Ltd
  • 17.27. Thermo Fisher Scientific Inc.
  • 17.28. THREAD Research, Inc.
  • 17.29. Veeva Systems Inc.
  • 17.30. Worldwide Clinical Trials, Inc.
  • 17.31. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CLINICAL TRIALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CLINICAL TRIALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CLINICAL TRIALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALYTICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOANALYTICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOANALYTICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOANALYTICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL MANAGEMENT & MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL MANAGEMENT & MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL MANAGEMENT & MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL WRITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL WRITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL WRITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT RECRUITMENT & RETENTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT RECRUITMENT & RETENTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT RECRUITMENT & RETENTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL REGULATORY & SAFETY MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REGULATORY & SAFETY MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REGULATORY & SAFETY MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SAFETY & PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SAFETY & PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SAFETY & PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIAL MANAGEMENT PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIAL MANAGEMENT PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIAL MANAGEMENT PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ECONSENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ECONSENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ECONSENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ELECTRONIC DATA CAPTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ELECTRONIC DATA CAPTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ELECTRONIC DATA CAPTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RANDOMIZATION & TRIAL SUPPLY MANAGEMENT (RTSM) SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RANDOMIZATION & TRIAL SUPPLY MANAGEMENT (RTSM) SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RANDOMIZATION & TRIAL SUPPLY MANAGEMENT (RTSM) SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL REMOTE SOURCE DATA VERIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL REMOTE SOURCE DATA VERIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL REMOTE SOURCE DATA VERIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EXPANDED ACCESS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EXPANDED ACCESS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EXPANDED ACCESS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTERVENTIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTERVENTIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTERVENTIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ADAPTIVE CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADAPTIVE CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ADAPTIVE CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-RANDOMIZED CONTROLLED TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-RANDOMIZED CONTROLLED TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-RANDOMIZED CONTROLLED TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RANDOMIZED CONTROLLED TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RANDOMIZED CONTROLLED TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RANDOMIZED CONTROLLED TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBSERVATIONAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBSERVATIONAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBSERVATIONAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANALYTICAL STUDY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANALYTICAL STUDY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANALYTICAL STUDY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CASE-CONTROL STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CASE-CONTROL STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CASE-CONTROL STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COHORT STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COHORT STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COHORT STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSPECTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROSPECTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSPECTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETROSPECTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RETROSPECTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RETROSPECTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CROSS-SECTIONAL STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CROSS-SECTIONAL STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CROSS-SECTIONAL STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DESCRIPTIVE STUDY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DESCRIPTIVE STUDY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DESCRIPTIVE STUDY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CASE REPORTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CASE REPORTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CASE REPORTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CASE SERIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CASE SERIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CASE SERIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POPULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POPULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POPULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHASE IV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHASE IV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PHASE IV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL FULL SERVICE OUTSOURCING (FSO) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL FULL SERVICE OUTSOURCING (FSO) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL FULL SERVICE OUTSOURCING (FSO) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL FUNCTIONAL SERVICE PROVIDER (FSP) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL FUNCTIONAL SERVICE PROVIDER (FSP) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL FUNCTIONAL SERVICE PROVIDER (FSP) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HYBRID OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HYBRID OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HYBRID OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL RARE DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL RARE DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL RARE DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESPIRATORY DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RESPIRATORY DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESPIRATORY DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACADEMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ACADEMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ACADEMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL COMPANY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPANY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL COMPANY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GOVERNMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL GOVERNMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL GOVERNMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL INDIVIDUAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL INDIVIDUAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL INDIVIDUAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 267. GCC CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 269. GCC CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. GCC CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 272. GCC CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 273. GCC CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 309. G7 CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 311. G7 CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. G7 CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 314. G7 CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 315. G7 CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 316. G7 CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 317. G7 CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 318. G7 CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 319. G7 CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 320. G7 CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 321. G7 CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 322. G7 CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 323. NATO CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. NATO CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 325. NATO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 326. NATO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 328. NATO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 329. NATO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 330. NATO CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 331. NATO CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 332. NATO CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 333. NATO CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 334. NATO CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 335. NATO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 336. NATO CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 337. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED STATES CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 352. CANADA CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. CANADA CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 354. CANADA CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 355. CANADA CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 356. CANADA CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 357. CANADA CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 358. CANADA CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 359. CANADA CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 360. CANADA CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 361. CANADA CLINICAL TRIALS MARKET SIZE, BY DESCRIPTIVE STUDY, 2018-2032 (USD MILLION)
  • TABLE 362. CANADA CLINICAL TRIALS MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 363. CANADA CLINICAL TRIALS MARKET SIZE, BY DELIVERY MODEL, 2018-2032 (USD MILLION)
  • TABLE 364. CANADA CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 365. CANADA CLINICAL TRIALS MARKET SIZE, BY SPONSORSHIP, 2018-2032 (USD MILLION)
  • TABLE 366. MEXICO CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. MEXICO CLINICAL TRIALS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 368. MEXICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 369. MEXICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 370. MEXICO CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN, 2018-2032 (USD MILLION)
  • TABLE 371. MEXICO CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, 2018-2032 (USD MILLION)
  • TABLE 372. MEXICO CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, 2018-2032 (USD MILLION)
  • TABLE 373. MEXICO CLINICAL TRIALS MARKET SIZE, BY ANALYTICAL STUDY, 2018-2032 (USD MILLION)
  • TABLE 374. MEXICO CLINICAL TRIALS MARKET SIZE, BY COHORT STUDIES, 2018-2032 (USD MILLION)
  • TABLE 375. MEXICO CLINICAL TRIALS MARKET SIZE, BY DE